Product Development and Commercialization
Search documents
Soligenix to Present at BIO Investment & Growth Summit
Prnewswire· 2026-02-24 12:30
Core Viewpoint - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs, and it will present at the BIO Investment & Growth Summit on March 2, 2026 [1] Company Overview - Soligenix is developing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and is seeking regulatory approvals following the successful completion of its second Phase 3 study [1] - The company is also expanding its product pipeline, which includes SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [1] - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine, and vaccines targeting filoviruses and COVID-19, utilizing the ThermoVax® heat stabilization technology [1] Upcoming Events - Christopher J. Schaber, Ph.D., President & CEO of Soligenix, will deliver a corporate presentation at the BIO Investment & Growth Summit on March 2, 2026, in Miami Beach, Florida [1] Funding and Support - The development of Soligenix's vaccine programs has been supported by government grants and contracts from agencies such as NIAID, DTRA, and BARDA [1]